title: HTK-solution (Bretschneider) for human liver transplantation. First clinical experiences.
abstract: The cardioplegic HTK-solution (Bretschneider) has not been used in human liver transplantation as yet. Herein the first results obtained from 14 patients with HTK-preserved liver grafts are presented. The suitability of HTK-solution could be shown. All grafts functioned primarily except one, where initial non-function was obviously due to donor reasons. The early postoperative peak values of transaminases as a sign of ischemic damage were average and similar to the values of other flushout solutions. Using HTK primary function could be achieved even in livers prospectively assessed as only of fair quality, and livers with poor donor function tests (MegX) functioned from the beginning. HTK-solution therefore seems to allow widening of the acceptance criteria for donor livers. It was not the aim of this trial to extend cold ischemic time, but 3 livers with 11 h and 12 h 25 showed immediate function. How far cold ischemic time can be extended is a still open question. All livers were rapidly cooled and homogeneously flushed out due to the low viscosity of HTK-solution. All livers had a soft consistency after perfusion indicating a low degree of cell edema. HTK therefore is an effective solution for liver preservation.
authors.affiliation: Klinik für Abdominal- und Transplantationschirurgie der Medizinischen Hochschule Hannover.
authors.forename: G
authors.initials: G
authors.lastname: Gubernatis
authors.forename: R
authors.initials: R
authors.lastname: Pichlmayr
authors.forename: P
authors.initials: P
authors.lastname: Lamesch
authors.forename: H
authors.initials: H
authors.lastname: Grosse
authors.forename: A
authors.initials: A
authors.lastname: Bornscheuer
authors.forename: H J
authors.initials: HJ
authors.lastname: Meyer
authors.forename: B
authors.initials: B
authors.lastname: Ringe
authors.forename: M
authors.initials: M
authors.lastname: Farle
authors.forename: H J
authors.initials: HJ
authors.lastname: Bretschneider
mesh_terms: D000241:Adenosine; D000410:Alanine Transaminase / Q000097:blood; D000493:Allopurinol; D001219:Aspartate Aminotransferases / Q000097:blood; D002314:Cardioplegic Solutions / Q000008:administration & dosage*; D005947:Glucose / Q000008:administration & dosage; D005978:Glutathione; D006085:Graft Survival / Q000187:drug effects; D006801:Humans; D006982:Hypertonic Solutions / Q000008:administration & dosage*; D007328:Insulin; D008111:Liver Function Tests; D016031:Liver Transplantation / Q000379:methods*; D008353:Mannitol / Q000008:administration & dosage; D009926:Organ Preservation / Q000379:methods*; D019188:Organ Preservation Solutions; D010477:Perfusion; D011183:Postoperative Complications / Q000209:etiology*; D011189:Potassium Chloride / Q000008:administration & dosage; D011343:Procaine / Q000008:administration & dosage; D011887:Raffinose; D012996:Solutions / Q000008:administration & dosage
chemical_list: C039984:Bretschneider cardioplegic solution; D002314:Cardioplegic Solutions; D006982:Hypertonic Solutions; D007328:Insulin; D019188:Organ Preservation Solutions; D012996:Solutions; C055206:University of Wisconsin-lactobionate solution; D008353:Mannitol; D011343:Procaine; D000493:Allopurinol; D011189:Potassium Chloride; D001219:Aspartate Aminotransferases; D000410:Alanine Transaminase; D005978:Glutathione; D005947:Glucose; D000241:Adenosine; D011887:Raffinose